Revive Therapeutics Ltd. (RVVTF) 0.1310 $RVVTF Revive

New Post Public Reply Private Reply Replies (0) Message Board

Sep 20, 2016 at 9:17 AM

Revive Therapeutics Ltd. (RVVTF) 0.1310 $RVVTF

Revive Therapeutics Provides Clinical and Corporate Update
Marketwire Canada - Tue May 10, 6:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 10, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company"

(TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for gout and rare diseases such as cystinuria, Wilson's disease and Rett syndrome, today provided an update on the progress of its clinical activities for its drug candidate, Bucillamine, for the treatment of gout and cystinuria, as well as its corporate initiatives.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2016
Marketwired - Mon May 09, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 9, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company"

(TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on commercializing treatments for gout and rare diseases such as cystinuria, Wilson's disease and Rett syndrome, announced today its results for the three and nine months ended March 31, 2016. The unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the period may be viewed on SEDAR at www.sedar.com.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor
Marketwired - Tue Apr 19, 3:01PM CDT
Revive Therapeutics Ltd. ("Revive" or the "Company"

(TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett Syndrome, today announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout
Marketwired - Wed Jan 20, 6:01AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"

(TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced the issuance of U.S. Patent 9,238,018, titled, 'The Use of Bucillamine in the Treatment of Gout', by the U.S. Patent and Trademark Office (USPTO). The term of the newly issued patent extends to November 2033.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics to Present at Noble Capital Markets' Investor Conference
Marketwired - Tue Jan 19, 7:03AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"

(OTCQB: RVVTF)(TSX VENTURE: RVV), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that its Chief Executive Officer, Fabio Chianelli, will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19th at 4:30pm Eastern Standard Time.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics Announces DTC Eligibility of Its Common Shares
Marketwired - Tue Dec 08, 3:01PM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"

(OTCQB: RVVTF)(TSX VENTURE: RVV), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that the Depository Trust Company (DTC) has approved the Company's eligibility application for Revive Therapeutics Ltd. (CUSIP 761516103), effective December 7, 2015.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics Retains the Ruth Group to Build U.S. Investment Community Awareness
Marketwired - Mon Dec 07, 6:01AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"

, a New York City-based leading investor relations and financial communications agency dedicated to the healthcare industry. The Ruth Group (www.theruthgroup.com) will counsel management and execute on the development and implementation of a strategic investor relations program with the objective of increasing awareness of Revive with the investment community in the U.S.
JPM: 66.44 (+0.25), RVV.VN: 0.165 (+0.005)

Revive Therapeutics Announces Positive Final Results from Its Phase 2a Study for the Treatment of Acute Gout Flares
Marketwired - Tue Dec 01, 6:02AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"

(TSX VENTURE: RVV) (OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced positive final results from its phase 2a proof-of-concept clinical study of REV-002 (Bucillamine), an oral anti-inflammatory agent, for the treatment of acute gout flares.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2015
Marketwired - Thu Nov 26, 6:01PM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"

(TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced its results for the three months ended September 30, 2015. The unaudited condensed interim consolidated financial statements and related management's discussion and analysis for the three months ended September 30, 2015 may be viewed on SEDAR at www.sedar.com.
RVV.VN: 0.165 (+0.005)

Revive Therapeutics Announces Listing on the OTCQB Market Exchange
Marketwire Canada - Wed Nov 25, 6:00AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"

(TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that the Company's common shares have been listed for trading on the OTCQB(R) Market exchange in the United States under the symbol "RVVTF". The Company's common shares will continue to be traded on the Toronto TSX Venture Exchange under its existing symbol "RVV".
RVV.VN: 0.165 (+0.005)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Crystal Risotti: Leading IT Compliance in Healthcare

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

BusyBee AI Revolutionizes Classroom Feedback Efficiency

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...